A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)

Diabetes, Obesity and Metabolism

Volumn 18, Issue 5, 2016, Pages 475-482

  Dungan, K M ^a   Weitgasser, R ^b,c   Perez Manghi, F ^d   Pintilei, E ^e   Fahrbach, J L ^f   Jiang, H H ^f   Shell, J ^f   Robertson, K E ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SALZBURG   (Austria)

^d Division of Cardiology   (Argentina)

^e SC Consultmed SRL ^*  (Romania)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Dulaglutide; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

DULAGLUTIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERUCTATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADVERSE EFFECTS; AGED; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATIENT DROPOUT; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, SUBCUTANEOUS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; RECOMBINANT FUSION PROTEINS; SULFONYLUREA COMPOUNDS;

EID: 84975720736     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12634     Document Type: Article

References (30)

1. Stratton IM, Adler AI, Neil HA etal. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
2. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
3. Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med 2011; 123: 15-23.
4. Pongwecharak J, Tengmeesri N, Malanusorn N, Panthong M, Pawangkapin N. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci 2009; 31: 481-486.
5. AHA. Heart Disease and Stroke Statistics: 2005 Update. Dallas: American Heart Association, 2005.
6. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273-3277.
7. Davis TM, Peters KE, Bruce DG, Davis WA. Prevalence, incidence, and prognosis of hepatobiliary disease in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. J Clin Endocrinol Metab 2012; 97: 1581-1588.
8. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care 2015; 38: 373-375.
9. Glaesner W, Vick AM, Millican R etal. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296.
10. De la Pena A, Loghin C, Cui X etal. Pharmacokinetics of once weekly dulaglutide in patients with type 2 diabetes mellitus. Diabetes 2014; 63(Suppl. 1): A251.
11. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
12. Dmitrienko A, Tamhane AC. Gatekeeping procedures in clinical trials. In: Dmitrienko A, Tamhane AC, Bretz F, eds. Multiple Testing Problems in Pharmaceutical Statistics. New York: Chapman and Hall/CRC Press, 2009: 171-176.
13. Seaquist ER, Anderson J, Childs B etal. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013; 98: 1845-1859.
14. Blonde L, Jendle J, Gross J etal. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015; 385: 2057-2066.
15. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
16. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168-2176.
17. Wysham C, Blevins T, Arakaki R etal. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
18. Dungan KM, Povedano ST, Forst T etal. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-1357.
19. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015; 38: 2241-2249.
20. Dungan KM, Raz I, Skrivanek Z, Sealls W, Fahrbach JL. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes Obes Metab 2016; 18: 49-55.
21. VICTOZA [prescribing information]. Novo Nordisk Inc., Plainsboro, 2013. Available from URL: http://www.novo-pi.com/victoza.pdf. Accessed 12 August 2015.
22. BYETTA [prescribing information] AstraZeneca Pharmaceuticals, Wilmington. Available from URL: http://www.azpicentral.com/byetta/pi_byetta.pdf#page=1. Accessed 12 August 2015.
23. Buse JB, Henry RR, Han J etal. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
24. Marre M, Shaw J, Brandle M etal. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
25. Buse JB, Rosenstock J, Sesti G etal. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
26. Ferdinand KC, White WB, Calhoun DA etal. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014; 64: 731-737.
27. Blevins T, Pullman J, Malloy J etal. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
28. Pratley RE, Nauck M, Bailey T etal. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
29. DeVries JH, Bain SC, Rodbard HW etal. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 1446-1454.
30. Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 2015; 38: 1058-1066.